Abstract
BackgroundInsulin glargine (IG; original drug and biosimilar) is on the market in vial or pen presentations with different costs. The biosimilar drug is less expensive than the original drug.PurposeThe main...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
